Medical College of Wisconsin
CTSIResearch InformaticsREDCap

Neoadjuvant strategies for pancreatic cancer. Oncology (Williston Park) 2001 Jun;15(6):727-37; discussion 741-4, 747

Date

06/30/2001

Pubmed ID

11430206

Scopus ID

2-s2.0-0035375709 (requires institutional sign-in at Scopus site)   14 Citations

Abstract

Recent prospective and retrospective data suggest that the use of multimodality therapy combining pancreaticoduodenectomy with postoperative adjuvant chemotherapy (fluorouracil) and external-beam radiation therapy maximizes local tumor control and improves the length of survival in pancreatic cancer patients, compared with surgery alone. Since postoperative chemoradiation is often delayed in these patients due to the morbidity and prolonged recovery time associated with surgery, investigators are assessing the efficacy of administering chemoradiation before pancreaticoduodenectomy in patients with potentially resectable pancreatic adenocarcinoma. When given prior to surgery, chemoradiation is not delayed and patients found to have disease progression after chemoradiation are not subjected to an unnecessary laparotomy.

Author List

Evans DB, Wolff RA, Crane CH

Author

Douglas B. Evans MD Chair, Professor in the Surgery department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Adenocarcinoma
Antimetabolites, Antineoplastic
Antineoplastic Combined Chemotherapy Protocols
Deoxycytidine
Female
Fluorouracil
Humans
Male
Neoadjuvant Therapy
Pancreatic Neoplasms
Pancreaticoduodenectomy